With facilities in Washington State and South Carolina, CanCure is an anticancer drug development company aimed at maturing and advancing the firm's proprietary immunotherapeutic antibody platforms into clinic for cancer treatment. CanCure specializes in easily deliverable biotherapy drugs (antibodies) that can restore patientsâ own natural immune function to fight cancer. The firm's antibody-based therapeutic platform can target all cancer types at all stages, including cancers that have spread to distant organs (metastatic cancer) and failed to respond to current FDA approved therapy. CanCure plan development of current proprietary new class of cancer immunotherapy drug pipelines from bench into early stage clinic with current focus on taking the leading antibody CuraB10 (mAb B10G5) into Phase I/II clinical trial.
